NCT05374252View on ClinicalTrials.gov

Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients

PHASE3RecruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

May 7, 2022

Primary Completion Date

May 31, 2025

Study Completion Date

December 31, 2025

Conditions
Anal Canal Cancer Stage IIIAnal Squamous Cell CarcinomaAnal Canal CancerAnal Cancer
Interventions
DRUG

PD-1 inhibitor

Two cycles of concurrent PD-1 antibody sintilimab combined with mytomicin C, 5-fluorouracil and IMRT, followed by adjuvant sintilimab for six months

RADIATION

concurrent chemoradiotherapy

Two cycles of concurrent mytomicin C and 5-fluorouracil combined with IMRT

Trial Locations (1)

510630

RECRUITING

The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Sixth Affiliated Hospital, Sun Yat-sen University

OTHER